Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Inhibrx Biosciences, Inc. (INBX) had Normalized Income after Taxes of $-43.31M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-43.31M |
|
-- |
|
-- |
|
$42.90M |
|
$-42.90M |
|
$-0.41M |
|
$-43.31M |
|
$-43.31M |
|
$-43.31M |
|
$-43.31M |
|
$-43.31M |
|
|
Normalized Income after Taxes |
$-43.31M |
$-42.90M |
|
$-42.23M |
|
15.47M |
|
15.47M |
|
$-2.80 |
|
$-2.80 |
|
| Balance Sheet Financials | |
$223.39M |
|
$5.55M |
|
$19.25M |
|
$242.64M |
|
$43.64M |
|
$98.65M |
|
$104.56M |
|
$148.20M |
|
$94.44M |
|
$94.44M |
|
$94.44M |
|
14.48M |
|
| Cash Flow Statement Financials | |
$-35.90M |
|
$-0.02M |
|
$99.84M |
|
$152.60M |
|
$216.52M |
|
$63.92M |
|
$2.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.12 |
|
-- |
|
-- |
|
0.51 |
|
1.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-35.92M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-45.86% |
|
-45.86% |
|
-17.85% |
|
-22.43% |
|
$6.52 |
|
$-2.32 |
|
$-2.32 |
|